Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total transaction of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares in the company, valued at approximately $20,665,399.68. The trade was a 1.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Enliven Therapeutics Price Performance
Shares of ELVN opened at $21.08 on Friday. Enliven Therapeutics, Inc. has a 1-year low of $15.96 and a 1-year high of $30.03. The stock has a market cap of $1.03 billion, a PE ratio of -11.09 and a beta of 1.04. The firm has a fifty day moving average price of $21.31 and a 200 day moving average price of $23.76.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have weighed in on ELVN shares. BTIG Research started coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 target price on the stock. HC Wainwright lifted their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a report on Friday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $38.75.
View Our Latest Report on Enliven Therapeutics
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Polar Capital Holdings Plc lifted its holdings in shares of Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. Boxer Capital Management LLC purchased a new position in Enliven Therapeutics during the fourth quarter worth approximately $15,106,000. FMR LLC increased its position in shares of Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company's stock worth $160,804,000 after acquiring an additional 601,611 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Enliven Therapeutics in the third quarter worth $8,199,000. Finally, Janus Henderson Group PLC grew its holdings in Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock valued at $26,611,000 after purchasing an additional 313,019 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
